Analyst Price Target is $46.42
▼ -1.30% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for Roche in the last 3 months. The average price target is $46.42, with a high forecast of $46.42 and a low forecast of $46.42. The average price target represents a -1.30% upside from the last price of $47.03.
Current Consensus is
The current consensus among 11 investment analysts is to hold stock in Roche. This rating has held steady since November 2020, when it changed from a Buy consensus rating.
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.